C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Change in Account Payables of -$85000.0 for Q1 2026, up 86.82% year-over-year from -$45497.9 in Q1 2025, and up 81.99% quarter-over-quarter from -$472000.0 in Q4 2025.
C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2026) Analysis & Trends
C4 Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$85000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 86.82% year-over-year to -$85000.0; the TTM figure through Mar 2026 stood at $92000.0 (up 109.73% YoY), while the FY2025 annual figure was -$468000.0, down 293.28% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$85000.0, up from -$472000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.5 million in Q2 2025, with the low at -$1.7 million in Q3 2022.
- The 5-year median for Change in Account Payables is -$176000.0 (2024), against an average of -$219529.4.
- Peak annual rise in Change in Account Payables reached 314.55% in 2025, while the deepest fall reached 454.4% in 2025.
- C4 Therapeutics' Change in Account Payables stood at -$1.1 million in 2022, then jumped by 115.71% to $169000.0 in 2023, then tumbled by 204.14% to -$176000.0 in 2024, then sank by 168.18% to -$472000.0 in 2025, then jumped by 81.99% to -$85000.0 in 2026.
- Business Quant data shows CCCC's Change in Account Payables at -$85000.0 in Q1 2026, -$472000.0 in Q4 2025, and -$885000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 348,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 348,000.00 |
| Jun 30, 2026 | 348,000.00 |
| Mar 31, 2026 | -85,000.00 |
| Mar 31, 2026 | -85,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Jun 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | -645,000.00 |
| Mar 31, 2025 | -645,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |